Long-term safety of pirtobrutinib in people with leukemia or lymphoma
Checks long-term safety of pirtobrutinib in adults with CLL or lymphoma who finished earlier studies.
Plain-language title generated from the registry record
Registry title: A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Key facts
- Where
- Bologna and Milan, ItalySee the 2 sites
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who took part in an earlier Lilly-sponsored study of pirtobrutinib. It checks long-term safety and lets them keep getting treatment or follow-up visits.
- Age
- 18 years and older
- Sex
- Women and men can join.
- Earlier treatment
- The person must be taking part in an earlier Lilly-sponsored clinical study of pirtobrutinib.
Main reasons for not taking part
- Exclusion rules are set separately for each earlier study (in its own appendix).
Read by machine on 12 November 2026.
Where in Italy
- IRCCS-AOU di Bologna-Policlinico S.Orsola-MalpighiBologna, ItalyContact: Pier Luigi Zinzani (principal investigator)Taking people
- Ospedale San RaffaeleMilan, ItalyContact: Paolo Ghia (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06876649
- Record updated
- 2 March 2026
- Original description
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.Read full original descriptionShow less
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Inclusion: Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.